The appointment of genetics expert Michael Hayden as Teva Pharmaceutical's president of global R&D has some industry observers speculating that the generic drug giant is eyeing the personalized medicine market as part of its future growth strategy.

Hayden, who will also serve as the company's chief scientific officer, is professor of medical genetics at the University of British Columbia and Canada Research Chair in human genetics and molecular medicine. He founded the Center of Molecular Medicine and Therapeutics at the university.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.